JP2017501140A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017501140A5 JP2017501140A5 JP2016536248A JP2016536248A JP2017501140A5 JP 2017501140 A5 JP2017501140 A5 JP 2017501140A5 JP 2016536248 A JP2016536248 A JP 2016536248A JP 2016536248 A JP2016536248 A JP 2016536248A JP 2017501140 A5 JP2017501140 A5 JP 2017501140A5
- Authority
- JP
- Japan
- Prior art keywords
- cgvhd
- day
- cell transplantation
- ibrutinib
- medicament according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000003814 drug Substances 0.000 claims 16
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 6
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 5
- 229960001507 ibrutinib Drugs 0.000 claims 5
- 238000002054 transplantation Methods 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 238000010322 bone marrow transplantation Methods 0.000 claims 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 claims 2
- 230000000414 obstructive effect Effects 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000017760 chronic graft versus host disease Diseases 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000004761 fibrosis Effects 0.000 claims 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361910944P | 2013-12-02 | 2013-12-02 | |
| US61/910,944 | 2013-12-02 | ||
| US201461973178P | 2014-03-31 | 2014-03-31 | |
| US61/973,178 | 2014-03-31 | ||
| PCT/US2014/068177 WO2015084857A1 (en) | 2013-12-02 | 2014-12-02 | Methods of treating and preventing alloantibody driven chronic graft versus host disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020025682A Division JP2020105181A (ja) | 2013-12-02 | 2020-02-18 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017501140A JP2017501140A (ja) | 2017-01-12 |
| JP2017501140A5 true JP2017501140A5 (enExample) | 2018-01-25 |
Family
ID=53270044
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016536248A Ceased JP2017501140A (ja) | 2013-12-02 | 2014-12-02 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2020025682A Ceased JP2020105181A (ja) | 2013-12-02 | 2020-02-18 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2022188655A Ceased JP2023029899A (ja) | 2013-12-02 | 2022-11-25 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2024010504A Ceased JP2024072291A (ja) | 2013-12-02 | 2024-01-26 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2025054634A Pending JP2025118595A (ja) | 2013-12-02 | 2025-03-27 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020025682A Ceased JP2020105181A (ja) | 2013-12-02 | 2020-02-18 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2022188655A Ceased JP2023029899A (ja) | 2013-12-02 | 2022-11-25 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2024010504A Ceased JP2024072291A (ja) | 2013-12-02 | 2024-01-26 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
| JP2025054634A Pending JP2025118595A (ja) | 2013-12-02 | 2025-03-27 | 同種抗体により駆動される慢性移植片対宿主病を処置及び予防する方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (6) | US20150157634A1 (enExample) |
| EP (1) | EP3076975A4 (enExample) |
| JP (5) | JP2017501140A (enExample) |
| KR (2) | KR20230104754A9 (enExample) |
| CN (2) | CN105939717B (enExample) |
| AU (4) | AU2014360758B2 (enExample) |
| BR (1) | BR112016012158A2 (enExample) |
| CA (2) | CA3210338A1 (enExample) |
| EA (1) | EA201691020A1 (enExample) |
| IL (4) | IL315228A (enExample) |
| MX (2) | MX389020B (enExample) |
| PH (2) | PH12020552048A1 (enExample) |
| TW (3) | TWI743019B (enExample) |
| WO (1) | WO2015084857A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX348290B (es) | 2012-06-04 | 2017-06-05 | Pharmacyclics Llc | Formas cristalinas de un inhibidor de tirosina quinasa de bruton. |
| MX392373B (es) * | 2013-10-25 | 2025-03-24 | Pharmacyclics Llc | Uso de ibrutinib en el tratamiento de enfermedad injerto contra huesped cronica |
| AR102871A1 (es) | 2014-12-03 | 2017-03-29 | Pharmacyclics Llc | Métodos de tratamiento de fibrosis |
| ES2863700T3 (es) * | 2016-03-22 | 2021-10-11 | Mayo Found Medical Education & Res | Uso de inhibidores de ácido graso sintasa para tratar la fibrosis |
| WO2018002958A1 (en) * | 2016-06-30 | 2018-01-04 | Sun Pharma Advanced Research Company Limited | Novel hydrazide containing compounds as btk inhibitors |
| US20200054721A1 (en) * | 2016-10-21 | 2020-02-20 | Bruce R. Blazar | Materials and methods for treating or preventing graft-versus-host-disease |
| CZ2017787A3 (cs) | 2017-12-08 | 2019-06-19 | Zentiva, K.S. | Farmaceutické kompozice obsahující ibrutinib |
| WO2021038540A1 (en) | 2019-08-31 | 2021-03-04 | Sun Pharma Advanced Research Company Limited | Cycloalkylidene carboxylic acids and derivatives as btk inhibitors |
| US12496303B2 (en) | 2020-10-19 | 2025-12-16 | Washington University | Conditioning agents for use in allogeneic hematopoietic stem cell transplantation |
| US20240025990A1 (en) * | 2020-12-01 | 2024-01-25 | City Of Hope | Prevention and treatment of graft-versus-host disease (gvhd) |
| WO2022161484A1 (en) * | 2021-01-30 | 2022-08-04 | Beigene, Ltd. | Methods of treating chronic active antibody-mediated rejection using btk inhibitors |
| US20240287781A1 (en) | 2023-02-28 | 2024-08-29 | Toto Ltd. | Wall-mounted flush toilet |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6326469B1 (en) | 1994-04-22 | 2001-12-04 | Sugen, Inc. | Megakaryocytic protein tyrosine kinases |
| US20060182723A1 (en) * | 2005-01-25 | 2006-08-17 | Spellberg Brad J | Methods for treating refractory infections in neutropenic individuals |
| US7625880B2 (en) * | 2006-01-13 | 2009-12-01 | Pharmacyclics, Inc. | Inhibitors of tyrosine kinases and uses thereof |
| EA018573B1 (ru) * | 2006-09-22 | 2013-09-30 | Фармасайкликс, Инк. | Ингибиторы тирозинкиназы брутона |
| JP5369183B2 (ja) * | 2008-07-16 | 2013-12-18 | ファーマサイクリックス，インク． | 固形腫瘍の治療用のブルートンのチロシンキナーゼの阻害剤 |
| EP2424368B1 (en) * | 2009-04-29 | 2014-12-31 | Locus Pharmaceuticals, Inc. | Pyrrolotriazine compounds |
| JP2013503204A (ja) * | 2009-08-31 | 2013-01-31 | アンプリミューン， インコーポレイテッド | Ｂ７−ｈ４融合タンパク質およびその使用方法 |
| US20120087915A1 (en) * | 2010-06-03 | 2012-04-12 | Pharmacyclics, Inc. | Use of inhibitors of bruton's tyrosine kinase (btk) |
| US20120071497A1 (en) * | 2010-06-03 | 2012-03-22 | Pharmacyclics, Inc. | Methods of treating abc-dlbcl using inhibitors of bruton's tyrosine kinase |
| BR112014000314A2 (pt) * | 2011-07-08 | 2017-01-10 | Novartis Ag | derivados de pirrolo pirimidina |
| ES2681050T3 (es) * | 2012-04-11 | 2018-09-11 | Acerta Pharma B.V. | Inhibidores de la tirosina quinasa de Bruton para la movilización hematopoyética |
| US10722577B2 (en) * | 2012-05-25 | 2020-07-28 | Sloan Kettering Institute For Cancer Research | Methods for treating GI syndrome and graft versus host disease |
| WO2014127200A1 (en) * | 2013-02-15 | 2014-08-21 | Immunomedics, Inc. | Chimeric and humanized anti-histone antibodies |
| MX392373B (es) * | 2013-10-25 | 2025-03-24 | Pharmacyclics Llc | Uso de ibrutinib en el tratamiento de enfermedad injerto contra huesped cronica |
| IL315294A (en) * | 2015-03-03 | 2024-10-01 | Pharmacyclics Llc | Pharmaceutical formulations of bruton's tyrosine kinase inhibitor |
-
2014
- 2014-12-02 TW TW103141826A patent/TWI743019B/zh active
- 2014-12-02 TW TW110135203A patent/TW202228700A/zh unknown
- 2014-12-02 BR BR112016012158A patent/BR112016012158A2/pt not_active Application Discontinuation
- 2014-12-02 IL IL315228A patent/IL315228A/en unknown
- 2014-12-02 US US14/558,297 patent/US20150157634A1/en not_active Abandoned
- 2014-12-02 CA CA3210338A patent/CA3210338A1/en active Pending
- 2014-12-02 KR KR1020237021643A patent/KR20230104754A9/ko active Pending
- 2014-12-02 KR KR1020167015178A patent/KR20160085817A/ko not_active Abandoned
- 2014-12-02 MX MX2016006955A patent/MX389020B/es unknown
- 2014-12-02 CN CN201480074674.4A patent/CN105939717B/zh active Active
- 2014-12-02 PH PH1/2020/552048A patent/PH12020552048A1/en unknown
- 2014-12-02 IL IL292522A patent/IL292522A/en unknown
- 2014-12-02 TW TW112113060A patent/TW202402295A/zh unknown
- 2014-12-02 CN CN201910760757.3A patent/CN110478353B/zh active Active
- 2014-12-02 WO PCT/US2014/068177 patent/WO2015084857A1/en not_active Ceased
- 2014-12-02 CA CA2932255A patent/CA2932255C/en active Active
- 2014-12-02 EA EA201691020A patent/EA201691020A1/ru unknown
- 2014-12-02 AU AU2014360758A patent/AU2014360758B2/en active Active
- 2014-12-02 EP EP14867905.3A patent/EP3076975A4/en active Pending
- 2014-12-02 JP JP2016536248A patent/JP2017501140A/ja not_active Ceased
-
2016
- 2016-05-18 IL IL245715A patent/IL245715A0/en unknown
- 2016-05-27 MX MX2022000209A patent/MX2022000209A/es unknown
- 2016-06-02 PH PH12016501051A patent/PH12016501051A1/en unknown
-
2017
- 2017-12-01 US US15/829,087 patent/US20180078558A1/en not_active Abandoned
-
2020
- 2020-02-18 JP JP2020025682A patent/JP2020105181A/ja not_active Ceased
- 2020-06-26 AU AU2020204276A patent/AU2020204276A1/en not_active Abandoned
- 2020-07-29 US US16/942,151 patent/US20210177854A1/en not_active Abandoned
- 2020-08-12 IL IL276683A patent/IL276683A/en unknown
-
2022
- 2022-04-29 US US17/733,419 patent/US20230100137A1/en not_active Abandoned
- 2022-06-02 AU AU2022203810A patent/AU2022203810B2/en not_active Expired - Fee Related
- 2022-11-25 JP JP2022188655A patent/JP2023029899A/ja not_active Ceased
-
2023
- 2023-09-25 US US18/372,495 patent/US20240293409A1/en not_active Abandoned
-
2024
- 2024-01-26 JP JP2024010504A patent/JP2024072291A/ja not_active Ceased
- 2024-12-17 AU AU2024278490A patent/AU2024278490A1/en active Pending
-
2025
- 2025-01-16 US US19/024,203 patent/US20250381188A1/en active Pending
- 2025-03-27 JP JP2025054634A patent/JP2025118595A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017501140A5 (enExample) | ||
| JP2012532874A5 (enExample) | ||
| WO2014205229A8 (en) | Use of high dose pridopidine for treating huntington's disease | |
| WO2009043476A3 (en) | Neuromedin s as a therapeutic agent | |
| WO2009043505A3 (en) | Use of beta-melanotropin as a therapeutic agent, eg for the treatment of aids or alzheimer | |
| NZ625592A (en) | Compositions and methods for the treatment of hepatic diseases and disorders | |
| SG10201407013QA (en) | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases | |
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| JP2016517888A5 (enExample) | ||
| WO2009033711A3 (en) | Use of glp-1 as a therapeutic agent | |
| WO2009033762A3 (en) | Use of endothelin-3 as a therapeutic agent | |
| WO2009033789A3 (en) | Use of a peptide as a therapeutic agent | |
| WO2009033739A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2015517489A5 (enExample) | ||
| WO2009040048A3 (en) | Use of the c-reactive peptide as a therapeutic agent | |
| WO2009033764A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2012517987A5 (ja) | 吸入用の医薬組成物のｆｐｄ特性を設定する方法 | |
| WO2009033781A3 (en) | Use of k237 as therapeutic agent | |
| WO2009033757A3 (en) | Use of mage-3 antigen (271-279) as a therapeutic agent | |
| WO2009033766A3 (en) | Use of a peptide as a therapeutic agent | |
| HK1206246A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| WO2009033723A3 (en) | Use of aip2 as a therapeutic agent | |
| JP2013541583A5 (enExample) | ||
| WO2009033745A3 (en) | Use of a peptide as a therapeutic agent | |
| JP2019535760A5 (ja) | ガボキサドールを用いた注意欠陥多動性障害（ａｄｈｄ）の治療方法 |